Market news

WSW, NY, September 25th, 2026, FinanceWireThree months ago, Nuvectis Pharma (NASDAQ:NVCT) was an oncology developer anchored by a single early-stage program. Today it holds ex-China rights to the world's first

Fort Lee, NJ, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference: Fireside Chat, Friday, September 11, 2026 at 9:10 AM ET. Webcast li

NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers.

Detailed price information for Nuvectis Pharma Inc (NVCT-Q) from The Globe and Mail including charting and trades.

Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group (“Haisco”), transforming the company into a late-stage clinical development organization.The Company’s lead drug candidate, Ciprocopan (NXP100), a Complement Factor B inhibitor for once-daily, oral administration, was approved in China in July 2026 for the treatment of patients with PNH Previously Untreated with Complement Inhibitors.Completed follow-on offeri

The mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 56.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

WSW, NY, July 23rd, 2026, FinanceWireNuvectis Pharma (NASDAQ:NVCT) announced this morning that ciprocopan (NXP100) has been approved by China's National Medical Products Administration (NMPA) for the treatment of

First global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy and safety data from Haisco's broad completed clinical development program in PNHCiprocopan application for marketing approval in China for the treatment of patients with PNH previously treated with anti-C5 therapies is currently under reviewCiprocopan has the potential to become an effective therapy in multiple complement-mediated diseases and provide a convenience advantag

New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease player following its June licensing deal with Haisco Pharmaceutical Group. Report highlights:Nuvectis Pharma (NASDAQ: NVCT) recently secured worldwide rights outside China to NXP100, a potentially best-in-class once-daily oral therapy for paroxysmal nocturnal hemoglobinuria (PNH), along with oncology asset NXP200, from Haisco Pharmaceutical Group. The deal,

WSW, NY, July 9th, 2026, FinanceWireIn June, Nuvectis Pharma (NASDAQ:NVCT) signed a deal that took it from a single-drug oncology company to the owner of one of the more closely watched assets in rare-disease medicine:

The consensus price target hints at a 61.5% upside potential for Nuvectis Pharma (NVCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.